DBV Technologies S.A.
DBVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesDBVTF
Q2 2022 vs. Q1 2022
How the institutions holding DBV Technologies S.A. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 31 | 38 | +7 |
| Shares | 20.4M | 26.0M | +5.61M (+27.5%) |
| Value | $32.9M | $66.8M | +$33.9M (+103.0%) |
New holders (10)
Institutions that held DBV Technologies S.A. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Fairmount Funds Management LLC | 4,831,155 | $12.3M | 2.82% |
| Schonfeld Strategic Advisors LLC | 183,867 | $469.0K | 0.00% |
| ExodusPoint Capital Management, LP | 138,122 | $352.0K | 0.00% |
| Toroso Investments, LLC | 51,584 | $132.0K | 0.00% |
| Two Sigma Investments, LP | 19,854 | $51.0K | 0.00% |
| BNP Paribas Arbitrage, SA | 19,087 | $48.7K | 0.00% |
| Kestra Advisory Services, LLC | 11,100 | $28.0K | 0.00% |
| Advisory Services Network, LLC | 10,000 | $26.0K | 0.00% |
| Barclays PLC | 284 | $1.00K | 0.00% |
| Parallel Advisors, LLC | 378 | $1.00K | 0.00% |
Sold out (3)
Institutions that held DBV Technologies S.A. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Optiver Holding B.V. | 22,472 | $36.0K |
| Millennium Management LLC | 22,116 | $35.0K |
| Personal Cfo Solutions, LLC | 16,088 | $26.0K |